Prabhakar has joined USP in January of 2020 and he is currently the Senior Director of Pharmaceutical Sciences, General Chapters, and works with Dosage Forms and Packaging & Distribution Expert Committee related activities. He is also the scientific lead for the Complex Generics initiatives at USP, including developing standards for Extractables & Leachables, as well as other complex products such as Complex Injectables, Ophthalmics, Topical & Transdermal, Nasal & Inhalation products. 

Prior to joining USP, Prabhakar worked in the pharmaceutical industry for more than 27 years at various small and large pharmaceutical companies in the field of analytical and bio-analytical chemistry. His expertise includes analytical and bioanalytical method development and validations, use of modern analytical technologies such as HPLC/UPLC and LC-MS/MS for characterization of both small and large molecules, use of automated instrumentation (TPW, and Sotax AT MD) for assay and dissolution testing, ICH stability testing, and preparation of regulatory documentation for IND/ANDA/NDA submissions. Prabhakar has BS and MS degrees in chemistry and PhD degree in bioanalytical chemistry.

With over 30 years of executive leadership in pharmaceutical analytical development, Arun has built and led high-performing global teams, consistently delivering successful ANDA approvals.

Over the course of his career, Arun has demonstrated deep scientific and technical expertise in the development and characterization of APIs and drug products. In recent years, he has driven regulatory approvals across complex platforms, including iron colloids, peptides, liposomes, microspheres, nanosuspensions, and nano-emulsions. He has also established a strong analytical foundation for oligonucleotide-based products.

Throughout his career, Mr. Mendiratta has defined and executed global analytical and regulatory strategies grounded in Quality by Design (QbD) principles. By implementing robust, science-driven control frameworks, he has consistently enabled first-cycle and timely global approvals.

Beyond product development, Arun has led end-to-end functions spanning Analytical Research, Corporate Quality Control, Quality Excellence, Innovation, and Quality Management. His leadership has driven sustained compliance, operational excellence, and strong performance across Generics APIs, oral solid dosage (OSD) formulations, and complex injectable portfolios.

Currently, Mr. Mendiratta serves as Executive Vice President and Head of Global Formulation Analytical Development at Micro Labs. Prior to joining Micro Labs, he held key positions at Ranbaxy, Aurobindo Pharma, and Viatris.

Dr. Prabhat Shrivastava, M. Pharm., PhD, is Associate Director & Vertical Head – Formulation & Packaging Development, Product Development at Piramal Pharma Solutions, Piramal Pharma Ltd., Ahmedabad, India. 

He is a technically skilled, strategic, and resilient pharmaceutical professional with 20 years of experience across Torrent, Wockhardt, Lupin, IIT-BHU, Novartis, and Piramal Pharma, with extensive expertise in the product development lifecycle and project management. His core competencies include complex and oncology oral solid dosage (OSD) product and analytical development, Quality by Design (QbD), biopharmaceutics, global regulatory affairs, GMP/GLP quality and compliance, clinical operations, stakeholder management, CDMO/CMO business, and people development. 

Since May 2022, he has been leading Formulation & Packaging Development at Piramal Pharma Solutions. Previously, he served as Senior Expert – Product Development at Novartis Healthcare, Manager and Group Lead – Product Development at Torrent Pharmaceuticals, Manager – Regulatory Affairs at Freyr Inc., Research Scientist at Wockhardt Research Centre, Senior Research Fellow at IIT-BHU, and Research Associate at Lupin Research Park. 

He holds a PhD in Pharmaceutical Engineering from IIT-BHU, a Master of Pharmacy from RGPV, Bhopal, and a Bachelor of Pharmacy from RGPV, Bhopal. His professional achievements include research awards, international travel grants, an AAPS Drug Design and Discovery travel award, a DBT international grant, and the D. S. Kothari Post-Doctoral Fellowship.

Mukesh is one of the founder directors of Ortiv-Q3 (A Sotax joint venture), a pioneering pharmaceutical research and testing organization well acknowledged globally for its specialized skill set in IVRT, Q2/Q3 characterization and complex parenterals formulation development. He is a pharmaceutical veteran with over 30 years of industrial experience. 

He earned his M Pharm (Pharmaceutics) from Jamia Hamdard, New Delhi in (1992) and Ph.D. (2021) from BAMU, Aurangabad. His expertise includes Niche steriles, Value added generics, Topicals and NCEs. He holds 18+ US/EU Patents/Application to his credit and is specially versed in nanotechnology-based platforms including Nanoemulsions, Nanosuspensions, Liposomes, Microspheres, Insitu forming depots and associated Q2/Q3 characterization. He has profound knowledge in formulation development, Quality & compliance, preclinical evaluation, process development, optimisation, and scale-up of formulations for regulated markets. 

In his past assignments he was associated with many reputed companies like Ranbaxy, Dabur Pharma, Fresenius Kabi, Emcure, Wockhardt and Claris in Sr positions like, Asst. Director, AVP & Technical head (R&D). He is co-inventor of the innovative microdialysis based IVRT technology developed by Ortiv-Q3 which has been successfully commercialized globally (patent applied). He is also the co-inventor of indigenously developed patented nanoparticle technology for Polymeric micellar delivery of Paclitaxel (NanoxelTM - Fresenius Kabi) that reached from bench scale to the market. He contributed in many products approvals for various markets including US, EU in his past career. He has also been ranked as the top 2% most-cited scientists in a list published by Stanford University (2021).

Graduated from ABCP College in 2001 and completed post-graduation from Goa College of Pharmacy in 2003, followed by a Ph.D. from SNDT Women's University, Mumbai. She began her career in Research and Development with Cosmo Group of Companies and subsequently worked with reputed pharmaceutical organizations including Macleods Pharmaceuticals, Aurobindo Pharma, Rubicon Research Ltd and Indoco remedies. She is currently serving as Vice President – Research & Development at Raay Neo Pharma.

With over 23 years of rich experience in formulation R&D for regulated markets such as the US, EU, UK, Canada, and Australia, she possesses extensive expertise in the development of complex sterile formulations, including ophthalmics and injectables, as well as challenging oral and inhalation dosage forms & nutraceuticals . Her experience spans immediate-release and extended-release tablets, multiparticulates, capsules, and semisolid formulations.

Throughout her career, she has successfully filed numerous ANDAs and First-to-File (FTF) products across global markets. Her expertise covers the complete product lifecycle—from lab-scale development to commercialization—effectively addressing technical and regulatory challenges to ensure successful market entry.

She has strong proficiency in Quality by Design (QbD), enabling robust product development and seamless technology transfer with minimal failure rates. She has also authored several research publications and holds multiple patents to her credit.

Dr. Saurabh Srivastava has earned his Ph.D. in Pharmaceutics from “Panjab University, Chandigarh”and pursued his Master's in Pharmaceutical Sciences from “Birla Institute of Technology and Science (BITS), Pilani, Rajasthan. He carries more than 17+ years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Mumbai, Wockhardt research centre, Aurangabad and His latest stint was with Dr. Reddy’s Laboratories, Hyderabad, as Tech Lead for development and commercialization of various Differentiated, NDA and ANDA based products for different regulated markets. 

Currently, he is working as a Professor & Head in the Department of Pharmaceutics, NIPER-Hyderabadandalsoacting as Associate Dean, of NIPER Hyderabad. His Research Laboratory,famed asPharmaceutical Innovation and Translational Research Lab (PITRL) is predominantly working on the development and optimization of Industrially viableDifferentiated formulations; (505(b)2, through the utilization of Micro/Nanostructured Targeted drug deliveries along with Novel platform technologies. His major therapeutic area of research is Cancer, Dermal Disorder, Diabetic Complications and Neurodegenerative disorders. 

He has mentored 55+ Masters Research scholars, and 08 PhD Thesis submissions; whereas,07 PhD Scholars are pursuing their Doctoral research under his supervision. His research team is actively involved in executing several Extra Mural Research (EMR) and Industrial Research Projects (~1.5 CR.)to establish novel differentiated products. He has been awarded several appreciation and recognitions from Dr. Reddy’s Laboratories for his outstanding contribution to research. He was further elected as a Fellow of the Prestigious “Telangana Academy of Sciences” (TAS) in May 2024. He had been instrumental in03 “Commercial Products”,and carries 17+ “International and National Patents”,04 Edited books, 50+ Book chapters along with 225+ Publications in Journals of International repute with h-Index of 44and 8800+ citations further to his credit.

Dr Raghupathi Kandarapu currently serves as Vice President and head of technology transfer and scientific aspects of new product launch and life-cycle management of generic products at Medreich Limited. Dr Kandarapu is an alumnus of National Institute of Pharmaceutical Education and Research (NIPER), Mohali (Punjab). After completing his MPharm and PhD programs from NIPER, Dr Kandarapu spent more than two decades with major Indian pharmaceutical companies at different capacities and mentored cross-functional teams involved in the development, registration, and commercialization of novel/innovative drug delivery systems as well as complex generics for highly regulated markets.  

Dr Kandarapu holds several certifications including advanced leadership program in business development from IIM-A Campus, Project Management (PM-BOK) from PM-Soft®, Clinical Research (ICRI, New Delhi), Intellecutual Property Rights, etc. 

He has published more than dozen research papers in international journals and presented research work in several conferences. He has more than 30 patent applications filed to his credit and member of academic counsel of several Indian universities, including NIPER- Guwahati.

Dr Kandarapu research focus includes identification and/or conceptualization of novel drug-delivery ideations based on “un-met” medical need life-cycle management of drugs/formulations. The core areas of specialization of his interest are Multiparticulate Drug Delivery Systems (MUPS), solid-state characterization, novel salt/polymorph screening for 505(b)(2) or exclusive marketing opportunities.

Dr. Pradeep Dabhi is a Co-Founder and Chief Scientific Officer of Cutyx Research, Ahmedabad, India, where he leads analytical development activities for complex drug delivery systems. His current work focuses on phase-appropriate analytical development and characterization of topical semi-solids, transdermal patches, oral thin strips/films, and microneedle array patches.

With more than 16 years of experience in pharmaceutical R&D, Dr. Dabhi has developed broad expertise spanning complex drug product development, analytical science, advanced product characterization, and regulatory CMC. His areas of expertise include analytical strategy and method development, qualification, validation and transfer; reverse engineering of complex formulations; in-vitro release and skin permeation testing (IVRT/IVPT); extractables and leachables (E&L); nitrosamine and elemental impurity assessment; and statistical evaluation of complex pharmaceutical data. He has contributed to development programs supporting ANDA and NDA 505(b)(2) pathways and has extensive experience addressing complex CMC requirements and regulatory deficiencies.

Dr. Dabhi is a Member of the CRCG–FDA Stakeholder Expert Committee on Adhesion Testing for Transdermal/Topical Delivery Systems, contributing to scientific efforts toward improved in-vitro approaches for evaluating adhesion performance of transdermal systems. He is also a Member of the USP Expert Committee on Excipient Chapters, contributing to the development and maintenance of pharmacopeial standards related to excipients.

In addition to his scientific and regulatory expertise, he has extensive experience in establishing analytical and quality-control capabilities for complex drug products, including greenfield laboratory development and implementation. Dr. Dabhi holds a Doctorate in Pharmaceutical Sciences and an M.S. (Pharm.) from NIPER- Ahmedabad, India.